HK Stock Market Move | ASCENTAGE-B(06855) increased by more than 3%. BTK degrader class 1 new drug APG-3288 tablets approved for clinical use.

As of the time of publication, ASCENTAGE-B (06855) has risen by more than 3%, with a current increase of 2.6% to HKD 47.44, with a turnover of HKD 31.5152 million. On the news front, according to a report from Medicine Observation, on February 2nd, the China National Medical Products Administration Drug Evaluation Center (CDE) website announced that the 1st class new drug APG-3288 tablet declared by Ascent Medical has been approved for clinical trials, aimed at developing treatments for relapsed/refractory hematologic malignancies. Public information shows that this is a new generation BTK targeted protein degradation therapy developed by Ascent Medical. The product has already been approved for clinical trials in the United States in August this year, aimed at treating relapsed/refractory B-cell malignancies. APG-3288 is the first new and highly effective and selective BTK degrader developed independently by Ascent Medical. The molecule promotes the formation of ternary complexes, followed by BTK degradation through proteasomes. Preclinical research results show that compared to other BTK degraders under development, APG-3288 has stronger BTK degradation ability, higher selectivity, and superior PK characteristics, showing great potential.